Department of Pathobiology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, Italy.
Mediators Inflamm. 2018 Feb 8;2018:3705389. doi: 10.1155/2018/3705389. eCollection 2018.
The "" has long represented for humans a dream, a vanity's sin for remaining young and to long survive. Today, because of , the research of antiageing interventions appears to be more important than ever, for preserving health in old age and retarding/or delaying the onset of age-related diseases. A hope is given by experimental data, which evidence the possibility of retarding ageing in animal models. In addition, it has been also demonstrated in animal life-extending studies not only the possibility of increasing longevity but also the ability to retard the onset of age-related diseases. Interestingly, this recent evidence is leading to promise of obtaining the same effects in humans and resulting in benefits for their health in old ages. In order to achieve this goal, different approaches have been used ranging from pharmacological targeting of ageing, basic biological assays, and big data analysis to the recent use of young blood, stem cells, cellular, genetic, and epigenetic reprogramming, or other techniques of regenerative medicine. However, only a little fraction of these approaches has the features for being tested in clinical applications. Here, new emerging molecules, drugs, and procedures will be described, by evidencing potential benefits and limitations.
“长生不老”一直是人类的梦想，一种追求青春永驻和长寿的虚荣之罪。如今，由于抗衰老干预措施的研究，保持老年健康和延缓/延迟与年龄相关的疾病的发生比以往任何时候都更加重要。实验数据提供了希望，这些数据表明在动物模型中延缓衰老的可能性。此外，在动物延长寿命的研究中，不仅证明了延长寿命的可能性，还证明了延缓与年龄相关的疾病发生的能力。有趣的是，最近的这一证据表明，有可能在人类身上获得相同的效果，并为他们的老年健康带来益处。为了实现这一目标，已经使用了不同的方法，从针对衰老的药物靶向治疗、基础生物学检测和大数据分析，到最近使用年轻血液、干细胞、细胞、遗传和表观遗传重编程或其他再生医学技术。然而，只有一小部分这些方法具有在临床应用中进行测试的特征。在这里，将描述新出现的分子、药物和程序，证明其潜在的益处和局限性。
